Cargando…
Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
Antipsychotic drugs targeting dopamine neurotransmission are still the principal mean of therapeutic intervention for schizophrenia. However, about one third of people do not respond to dopaminergic antipsychotics. Genome wide association studies (GWAS), have shown that multiple genetic factors play...
Autores principales: | Rampino, Antonio, Marakhovskaia, Aleksandra, Soares-Silva, Tiago, Torretta, Silvia, Veneziani, Federica, Beaulieu, Jean Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338030/ https://www.ncbi.nlm.nih.gov/pubmed/30687136 http://dx.doi.org/10.3389/fpsyt.2018.00702 |
Ejemplares similares
-
M207. REVEALING HYPOTHALAMIC PATHWAYS CONTRIBUTION TO OLANZAPINE- INDUCED METABOLIC SYNDROME: FROM MURINE MODEL TO HUMAN TRANSLATION
por: Veneziani, Federica, et al.
Publicado: (2020) -
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019) -
Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics
por: Rampino, Antonio, et al.
Publicado: (2021) -
Olanzapine- induced metabolic syndrome pathogenesis: Hypothalamic “leptin resistance” or “pomc resistance”?
por: Veneziani, F., et al.
Publicado: (2021) -
Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)